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Background: In 1950, the association between cigarette smoking and 
lung cancer was ﬁrmly established. However, adenocarcinoma of the 
lung comprised only about 5% of lung cancers at the time and appeared 
unrelated to smoking. In the 1960s and 1970s, incidence of adenocarci-
noma increased sharply, and became strongly related to smoking. 
Methods: SEER data on 307,797 lung cancer patients diagnosed in the 
US between 1975 and 2003 were analyzed. The objective was to assess 
changes in age-standardized incidence rates (per 100,000 population) 
at diagnosis of the four major lung cancer histologies: adenocarcinoma, 
squamous cell carcinoma, small cell carcinoma and large cell carci-
noma. Incidence of each histologic subtype was measured during six 
time periods (1975-1979, 1980-1984, 1985-1989, 1990-1994, 1995-
1999, 2000-2003). Comparisons were drawn based upon gender, race, 
and age. Because SEER contains no data on cigarette smoking, other 
sources were utilized to correlate changing histology to time trends 
in smoking prevalence, the changing cigarette, and Tobacco Institute 
actions. 
Results: Among all patients, adenocarcinoma surpassed squamous car-
cinoma by 1980-1984 to become the most common histologic subtype. 
The incidence of adenocarcinoma rose 62% between 1975-1979 and 
1995-1999, but then fell 8% in 2000-2003. Squamous cell incidence 
peaked in 1980-1984 and dropped by 35% by 2000-2003. Adenocar-
cinoma surpassed squamous cell in 1985-1989 in men, while adeno-
carcinoma had already become the most common form of lung cancer 
in women by 1975-1979. Adenocarcinoma rose 38% in men from 
1975-1979 to 1995-1999, while it doubled in women during this inter-
val. Among whites, adenocarcinoma surpassed squamous carcinoma 
by 1980-1984, although this did not occur among blacks for another 
decade. Nonetheless, incidence rate of adenocarcinoma has consistently 
been signiﬁcantly higher among black males than in other subgroups, 
while incidence of adenocarcinoma has been nearly identical among 
white and black women. Adenocarcinoma was already most common 
among patients <50 yrs of age by 1975-1979, while adenocarcinoma 
rapidly increased and surpassed squamous carcinoma in all other age 
groups by 1990-1994. By 2000-2003, adenocarcinoma comprised 
47% of all lung cancers (42% in men; 52% in women; 59% in pts <50 
yrs). Currently, adenocarcinoma is the most common histology in both 
sexes, races, and in all age groups. 
Conclusions: The dramatic rise of adenocarcinoma of the lung is 
consistent with the hypothesis that changes in cigarette design and 
composition were the major factors that were responsible for this 
rise. This increase has been most striking among women and younger 
persons. Trends in adenocarcinoma correlate with the wide-scale adop-
tion by smokers of ﬁltered and low tar cigarettes, and with increasing 
nitrosamine levels in cigarettes. While ﬁltered cigarettes comprised 
only 1% of the market in 1950, their use rapidly increased to 64% in 
1964 and 95% in 1986. Today 98% of cigarettes made in the US are 
ﬁltered. Speciﬁcally, the use of ﬁlter vents in cigarette design likely 
played a substantial role in this rapid rise of adenocarcinoma of the 
lung. The use of ﬁlter vents reduces the resistance to draw allowing 
smokers to take bigger, deeper puffs thereby facilitating the delivery 
of smoke particles deep into the airways. These changes were intro-
duced by the Tobacco Industry in response to mounting evidence that 
cigarette smoking caused other forms of lung cancer. These actions by 
the Tobacco Industry contributed to the development of an epidemic of 
smoking-related adenocarcinoma of the lung.
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Background: This Phase III, randomized, open-label, multicenter, 
parallel-group study (INTEREST [IRESSA non-small-cell lung cancer 
(NSCLC) Trial Evaluating REsponse and Survival against Taxotere]), 
compared geﬁtinib with docetaxel in patients with locally advanced 
or metastatic NSCLC pretreated with platinum-based chemotherapy. 
This is the largest reported Phase III study comparing targeted therapy 
(geﬁtinib) with chemotherapy (docetaxel).
Methods: Patients (≥18 years, performance status [PS] 0-2) with lo-
cally advanced or metastatic NSCLC who had progressed or recurred 
following 1 or 2 prior chemotherapy regimens (at least 1 platinum-
based) were randomized to receive geﬁtinib (250 mg/day orally) or 
docetaxel (75 mg/m2 iv every 3 weeks). The primary objective was to 
compare overall survival between geﬁtinib and docetaxel using a co-
primary analysis in both the overall population (non-inferiority) and, as 
a protocol amendment following the emergence of biomarker data, in 
patients with high epidermal growth factor receptor (EGFR) gene copy 
number (measured by ﬂuorescence in situ hybridization) (superiority). 
Secondary endpoints were progression free survival, objective response 
rate (assessed by RECIST), patient-reported functionality and quality 
of life (measured using the Functional Assessment of Cancer Therapy-
Lung total score, trial outcome index and lung cancer subscale), and 
safety and tolerability (according to Common Toxicity Criteria version 
2.0). Exploratory endpoints including other biomarkers and quality of 
life endpoints were also assessed. A Cox proportional hazards model 
analysis adjusting only for randomized treatment was used to compare 
overall survival between the randomized treatments. 
